Pharma channel feed – Endpoints News

Pharma channel feed

Amgen comes up with $1.5B package to partner with CytomX on a preclinical Probody approach to cancer

8 years ago

Patients often demand experimental drugs that prove ineffective — report

8 years ago

Celgene joins the heavyweight partner club collaborating with Nimbus

8 years ago

Sam Kulkarni takes the helm at CRISPR Therapeutics as founding CEO steps down

8 years ago

In the wake of a drubbing, Vivek Ramaswamy gambles $116M on Arbutus’ hep B work

8 years ago

Eli Lilly R&D chief Jan Lundberg heads for the exit as CEO assembles a new team at the top

8 years ago

FDA commissioner Gottlieb's travel preferences? Commercial jets, a la mode

8 years ago

FDA experts turn thumbs down on PTC’s wobbly case for its Duchenne MD drug

8 years ago

AbbVie wins a 5-year free pass on mega-blockbuster Humira in biosim settlement with rival Amgen

8 years ago

Arcturus reverse merges into the market, steering RNA projects to the clinic

8 years ago

FDA rejects Intarcia’s hotly promoted diabetes drug/device, citing manufacturing issues

8 years ago

Allergan’s tribal treaty in Restasis patent fight triggers a Congressional donnybrook

8 years ago

Right after Trump blamed high drug prices on campaign cash, drugmakers gave more

8 years ago

Oh, no we aren’t! AbbVie says it isn’t rethinking pricing pledge at all

8 years ago

No time for formalities, Acorda scraps FDA meeting in scramble to re-file CVT-301

8 years ago

Former Zacks biotech analyst Napodano charged with fraud after settling with SEC on insider trading cases

8 years ago

EMA warns HQ move may cause major turmoil, seriously delaying new drug approvals

8 years ago

In a damning indictment, FDA review scorns PTC’s Duchenne drug for repeated failures

8 years ago

Genocea shelves its lead drug, slashes staff and switches focus to trendy neoantigens

8 years ago

Visualize: What would these 11 biotech companies look like without immigrants?

8 years ago

Allergan caps a bad day with news the FDA has kicked back a supplemental application for cariprazine

8 years ago

FDA spurns J&J's troubled rheumatoid arthritis drug sirukumab

8 years ago

AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs

8 years ago

House committee wants to know a lot more about the cyberattack that damaged Merck

8 years ago

First page Previous page 316 317 318319320 321 322 Next page Last page